Rapport Therapeutics (NASDAQ:RAPP) Director Steven Paul Purchases 35,714 Shares of Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) Director Steven Paul bought 35,714 shares of the company’s stock in a transaction that occurred on Thursday, October 22nd. The shares were bought at an average price of $27.28 per share, with a total value of $974,277.92. Following the transaction, the director owned 77,380 shares of the company’s stock, valued at $2,110,926.40. The trade was a 85.71% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Rapport Therapeutics Price Performance

Shares of RAPP stock traded up $1.47 during trading hours on Thursday, hitting $26.53. The stock had a trading volume of 1,453,606 shares, compared to its average volume of 407,078. Rapport Therapeutics, Inc. has a one year low of $23.75 and a one year high of $52.93. The stock’s 50-day moving average price is $39.86 and its two-hundred day moving average price is $39.07. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -8.73 and a beta of 1.22.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.07). As a group, equities research analysts predict that Rapport Therapeutics, Inc. will post -4.09 earnings per share for the current fiscal year.

Key Rapport Therapeutics News

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: RAP-219 is advancing to Phase 3. Rapport said the drug met both Phase 2 endpoints in bipolar mania, producing statistically significant placebo-adjusted improvements in manic symptoms and overall illness severity. The results strengthen the potential value of RAP-219 and expand its development opportunity beyond epilepsy. Rapport plans Phase III bipolar mania trials
• Positive Sentiment: Analysts continue to raise or maintain bullish targets. JonesTrading increased its price target from $50 to $82 and maintained a Buy rating. BTIG Research also raised its target, while HC Wainwright reaffirmed its Buy rating. Raymond James recently set an $86 target and maintained Strong Buy. The analyst activity suggests Wall Street sees substantial upside if RAP-219 succeeds in later-stage development. BTIG Research price target update HC Wainwright rating update
• Positive Sentiment: CFO Troy Ignelzi bought 5,500 shares for $143,550. The purchase increased his direct holdings by 55% to 15,500 shares, a potentially supportive signal of management confidence. SEC insider ownership filing
• Neutral Sentiment: The clinical results move RAP-219 toward Phase 3 but do not eliminate biotechnology risks, including trial execution, regulatory approval, funding needs, and eventual commercialization.
• Negative Sentiment: Some coverage characterized the trial outcome as narrower than investors initially hoped. Rapport also remains unprofitable, recently reporting quarterly EPS below consensus, which could limit gains if future clinical or financial results disappoint. Rapport bipolar data analysis

Analyst Upgrades and Downgrades

RAPP has been the topic of several recent analyst reports. Leerink Partners assumed coverage on shares of Rapport Therapeutics in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $52.00 target price on the stock. TD Cowen reissued a “buy” rating on shares of Rapport Therapeutics in a research note on Tuesday. BTIG Research boosted their price objective on Rapport Therapeutics from $75.00 to $89.00 and gave the company a “buy” rating in a report on Tuesday. Wolfe Research started coverage on Rapport Therapeutics in a research report on Thursday, October 15th. They issued an “outperform” rating and a $50.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Rapport Therapeutics presently has an average rating of “Buy” and a consensus price target of $68.36.

Hedge Funds Weigh In On Rapport Therapeutics

Several institutional investors have recently bought and sold shares of RAPP. TRV GP V LLC bought a new position in Rapport Therapeutics in the second quarter worth approximately $261,709,477. ARCH Venture Management LLC purchased a new stake in Rapport Therapeutics during the second quarter worth $155,376,512. BlackRock Inc. purchased a new stake in Rapport Therapeutics during the second quarter worth $112,500,000. Johnson & Johnson bought a new stake in Rapport Therapeutics during the 2nd quarter valued at $74,360,823. Finally, TRV GP VI LLC bought a new stake in Rapport Therapeutics during the 2nd quarter valued at $40,387,314.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.